Century Therapeutics, Inc. IPSC 深 沪
已收盘 01-09 16:00:00 美东时间
1.94
+0.170
+9.60%
华盛通- 最 高1.95
- 今 开1.80
- 成交量 235.81万股
- 最 低 1.74
- 昨 收 1.77
- 总市值 1.69亿
- 52周最高 1.95
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.3418
- 委 比 -19.12%
- 总股本 8730.71万
- 历史最高 32.899
- 量 比 0.41
- 振 幅 11.86%
- 历史最低 0.3418
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 获FDA支持加速药物上市！MoonLake大涨27%；Satellogic大涨21.7%
获FDA支持加速药物上市！MoonLake大涨27%；宣布获七位数地球观测合同，Satellogic涨超21%>>
01-09 16:01
Century Therapeutics Launches $135M Private Placement Offering Of ~117M common Shares, Warrants At $1.15/Share
Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced it has entered into
01-08 21:08
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
Leerink Partners Downgrades Century Therapeutics to Market Perform, Lowers Price Target to $2
Leerink Partners analyst Daina Graybosch downgrades Century Therapeutics (NASDAQ:IPSC) from Outperform to Market Perform and lowers the price target from $7 to $2.
2025-11-17 20:29
Century Therapeutics Q3 EPS $(0.40) Misses $(0.34) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.34) by 18.34 percent. This is a 8.11 percent decrease over losses of $(0.37) per share
2025-11-13 20:34
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Century Therapeutics announced that its Chief Scientific Officer, Chad Cowan, Ph.D., will present at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The presentation will be live-streamed on Century’s website and available for replay for 30 days. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancer using its Allo-Evasion™ technology. For more inform...
2025-10-14 20:01
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics' CEO Brent Pfeiffenberger will present at the H.C. Wainwright Global Investment Conference on September 9-10, 2025, in New York. An on-demand webcast of the presentation will be available on September 5, 2025, on the company’s website. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancers, focusing on off-the-shelf therapies to expand patient access.
2025-08-22 12:00
Century Therapeutics Announces Major Workforce Reduction
An announcement from Century Therapeutics ( ($IPSC) ) is now available. On July...
2025-07-08 04:29
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
Century Therapeutics to Present Two Abstracts at EULAR 2025 Congress The company will highlight data on its iPSC-derived cell therapy pipeline for autoimmune diseases and cancer. Abstracts include CNTY-101, a CD19-targeting CAR-NK product, and generation of CAR-NK, γδ CAR-T, and αβ CAR-T cells. Presentations by Hongxia Zhang, Ph.D. and Jonathan Kurtz, Ph.D. will occur on June 12. Additional materials will be available on the company’s website p...
2025-05-28 20:01
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
2025-05-17 08:44
